Reoccurring disappointment in development portfolios-why it happens and how to mitigate it.
Gary Summers
Advertisement
Articles by Gary Summers
Advertisement
Latest Updated Articles
Product Development: The Optimizer’s CursePublished: September 19th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
3
Merck to Acquire Cidara for $9.2 Billion
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
